Survey of US public attitudes toward pharmacogenetic testing
Authors:
Open Access
- 15 February 2011
- journal article
- research article
- Published by Springer Nature in The Pharmacogenomics Journal
- Vol. 12 (3) , 197-204
Abstract
To assess public attitudes and interest in pharmacogenetic (PGx) testing, we conducted a random-digit-dial telephone survey of US adults, achieving a response rate of 42% (n=1139). Most respondents expressed interest in PGx testing to predict mild or serious side effects (73±3.29 and 85±2.91%, respectively), guide dosing (91%) and assist with drug selection (92%). Younger individuals (aged 18–34 years) were more likely to be interested in PGx testing to predict serious side effects (vs aged 55+ years), as well as Whites, those with a college degree, and who had experienced side effects from medications. However, most respondents (78±3.14%) were not likely to have a PGx test if there was a risk that their DNA sample or test result could be shared without their permission. Given differences in interest among some groups, providers should clearly discuss the purpose of testing, alternative testing options (if available) and policies to protect patient privacy and confidentiality.Keywords
This publication has 42 references indexed in Scilit:
- The Impact of Information Order on Intentions to Undergo Predictive Genetic TestingJournal of Health Psychology, 2010
- Pharmacogenetics of WarfarinAnnual Review of Medicine, 2010
- Racial and Ethnic Disparities in Awareness of Genetic Testing for Cancer RiskAmerican Journal of Preventive Medicine, 2009
- Associations between Anticipated Reactions to Genetic Test Results and Interest in Genetic Testing: Will Self-Selection Reduce the Potential for Harm?Genetic Testing, 2008
- A lay prescription for tailor-made drugs—focus group reflections on pharmacogenomicsHealth Policy, 2005
- Availability of pharmacogenomics-based prescribing information in drug package inserts for currently approved drugsThe Pharmacogenomics Journal, 2004
- Attitudinal barriers to delivery of race-targeted pharmacogenomics among informed lay personsGenetics in Medicine, 2003
- Gene therapy and the public: a matter of trustGene Therapy, 2002
- Factors influencing anticipated decisions about genetic testing: Experimental studiesBritish Journal of Health Psychology, 1999
- Interest in Learning of Personal Genetic Risk for Cancer: A General Population SurveyPreventive Medicine, 1996